On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (NYSE:HIMS), an estimated $18.07 million trade based on quarterly average pricing.
Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded glucagon-like peptide-1 receptor agonists (GLP-1RAs), ending a long-running feud that ...
MarketBeat on MSN
Patience pays: Hims & Hers surges on news of Novo Nordisk deal
After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...
Shares of Hims & Hers Health (NYSE: HIMS) skyrocketed after the telemedicine platform came to an agreement with Novo Nordisk (NYSE: NVO) to sell the drugmaker's popular GLP-1 weight loss drugs. The ...
On Monday, Needham analyst Ryan MacDonald upgraded Hims and Hers from Hold to Buy with a price target of $30.00, stating the partnership alleviates concerns around legal risk and fundamentally changes ...
Investing.com -- Hims & Hers Health Inc was upgraded to “Neutral” from “Underperform” by Bank of America, which said a new agreement with Novo Nordisk removes a key legal risk that had weighed on the ...
Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more
Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped 3%. Bank of America upgraded the stock to neutral from underperform after ...
Novo Nordisk drops patent lawsuit against Hims & Hers after agreement to sell branded weight loss medicines on Hims platform. Shares of Hims & Hers jump 36%.
Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, payers and other industry players look to expand their businesses and gain a competitive edge. | CHS' ...
Hims & Hers Health Inc HIMS shares are rising higher on Tuesday. Multiple analysts upgraded the stock following the company’s deal with Novo Nordisk this week. Hims & Hers has struck a new agreement ...
On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.
Novo Nordisk will sell Wegovy and Ozempic drugs through the telehealth company Hims & Hers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results